Evidence map›Paper›PMID 26824986›Full record

ArticleOncotarget2016

Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.

Hio Chung Kang, Hong Kwan Kim, Sharon Lee, Pedro Mendez, James Wansoo Kim, Gavitt Woodard, Jun-Hee Yoon, Kuang-Yu Jen, Li Tai Fang, Kirk Jones and 2 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Molecular Characterization of Peritoneal Mesotheliomas.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Malignant pleural mesothelioma: an update.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Hio Chung KangThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Hong Kwan KimThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Sharon LeeCureSeq Inc, Brisbane, CA, USA.
Pedro MendezThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
James Wansoo KimCureSeq Inc, Brisbane, CA, USA.
Gavitt WoodardThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Jun-Hee YoonThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Kuang-Yu JenDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Li Tai FangThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Kirk JonesDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
David M JablonsThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Il-Jin KimThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
University of California, San Francisco · USSamsung Medical Center · KRUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood. Genetic alterations and causes for multiple primary cancer development including MPM are unknown. We used whole exome sequencing to identify somatic mutations in a patient with MPM and two additional primary cancers who had no evidence of venous, arterial, lymphovascular, or perineural invasion indicating dissemination of a primary lung cancer to the pleura. We found that the MPM had R282W, a key TP53 mutation, and genome-wide allelic loss or loss of heterozygosity, a distinct genomic alteration not previously described in MPM. We identified frequent inactivating SETDB1 mutations in this patient and in 68 additional MPM patients (mutation frequency: 10%, 7/69) by targeted deep sequencing. Our observations suggest the possibility of a new genetic mechanism in the development of either MPM or multiple primary cancers. The frequent SETDB1 inactivating mutations suggest there could be new diagnostic or therapeutic options for MPM.

Indexed as

Blotting, WesternExomeFemaleGenome, HumanHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansImmunoenzyme TechniquesLoss of HeterozygosityLung NeoplasmsMesotheliomaMesothelioma, MalignantMiddle AgedMutationPleural NeoplasmsPrognosisHistone-Lysine N-MethyltransferaseProtein MethyltransferasesRNA, MessengerSETDB1 protein, humanexome sequencinggenome-wide allelic lossmalignant pleural mesotheliomamultiple primary cancerSETDB1

Identifiers

PMID26824986
PMCPMC4884995
OpenAlexW2270944159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.